Three simple tests could save the NHS nearly £6.9 billion
Exploring HCV eradication through diagnosis and treatment strategies
Modelling the burden of non-muscle-invasive bladder cancer in Europe
Estimating the clinical impact and costs of implementing a point of care test for influenza A/B and respiratory syncytial virus on an acute paediatric hospital inpatient ward
A rapid influenza test in hospitals could avoid unnecessary paediatric isolation bed days and save costs
Performance of a novel point-of-care molecular assay for the detection of Influenza A, B and RSV in children
Mapping the diagnostic pathway for breast cancer in England and comparison to Europe
The cost of pelvic inflammatory disease and potential cost-savings of chlamydia screening
We worked with clinicians from St Georges University who had published a trial estimating the incidence of pelvic inflammatory disease (PID) among women screened and unscreened for chlamydia. Patient data was analysed, and the average cost of managing PID was estimated to be £163 in community and hospital settings, and that over £60,000 could be saved in London alone from screening for chlamydia. This paper has been cited widely and results have informed policy and further modelling studies.
Thinking critically about the value and cost of drugs: managing patients with invasive fungal disease
The benefits and cost-savings of a new point-of-care test for chlamydia and gonorrhoea
We developed an understanding of how sexual health clinics in England could use a rapid point of care test for two common sexually transmitted infections. We defined the current patient care pathways and found that the pathways could be streamlined and costs of care reduced by using point-of-care tests. The economic model developed by Aquarius Population Health showed that the test could deliver £10 million in cost savings, and give far more effective management of chlamydia and gonorrhoea at a population level.